Welcome to the Investor Relations section of CareFusion’s website. Here, we provide access to a variety of shareholder materials, including financial and stock information, corporate governance resources and access to our presentations and events. We are committed to providing you with convenient access to these resources, and if you need additional information, please contact us.
You can also sign up to receive email alerts when new company information is available by going to CareFusion’s Email Alerts page.
To receive printed copies of CareFusion investor materials by mail, you can submit an on-line request here. You may also send an email to email@example.com with your contact information and material request.
CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve patient care. The company develops market-leading technologies including Alaris® infusion pumps, Pyxis® automated dispensing and patient identification systems, AVEA® and LTV® series of ventilators and respiratory products, ChloraPrep® skin prep products, MedMined™ services for data mining surveillance, and V. Mueller® and Snowden-Pencer® surgical instruments.
SAN DIEGO, July 10, 2014 /PRNewswire/ -- CareFusion Corporation (NYSE: CFN) today announced plans to release fourth quarter and fiscal 2014 results on Thursday, Aug. 7, following the close of trading on the New York Stock Exchange.
The company will host a conference call on Aug. 7 at 2 p.m. PDT (5 p.m. EDT) to discuss the results for the quarter and year, ended June 30, 2014, as well as provide guidance for future periods. To access the call, visit the Investors page at www.carefusion.com....
SAN DIEGO, May 15, 2014 /PRNewswire/ -- CareFusion Corp. (NYSE: CFN), a leading, global medical technology company, today announced the successful pricing of three series of senior unsecured notes for an aggregate principal amount of $1 billion. Of these notes, $300 million will mature in 2017 and will bear interest at an annual rate of 1.450 percent; $400 million will mature in 2024 and will bear interest at an annual rate of 3.875 percent and $300 million will mature in 2044 and will bear...
Move Increases Size of Board to 10 Members
SAN DIEGO, May 7, 2014 /PRNewswire/ -- CareFusion (NYSE:CFN), a leading global medical technology company, today announced that Supratim Bose has been elected as the 10th member of its board of directors, effective immediately.
Bose is currently executive vice president and president, Asia-Pacific, Middle East and Africa for Boston Scientific Corporation, a position he has held since January 2013. He joined Boston Scientific in December 2...
- Third quarter revenue increased 7 percent to $968 million, driven by continued growth in the company's Procedural Solutions segment
- Diluted earnings per share (EPS) from continuing operations totaled $0.48 on a GAAP basis and increased 2 percent to $0.60 per adjusted share
- Company narrows and updates fiscal 2014 revenue, EPS and cash flow guidance
SAN DIEGO, May 5, 2014 /PRNewswire/ -- CareFusion Corp. (NYSE: CFN), a leading, global medical technology company, today reported ...
Cautions Concerning Forward-Looking Statements: This website contains statements that are forward-looking and consequently are subject to risks and uncertainties. Examples of these statements include statements regarding our financial guidance, our expectations regarding hospital capital spending, our expected standup costs and other costs related to the separation from Cardinal Health and other statements regarding matters that are not historical facts. You should be aware that certain factors may affect us in the future and could cause actual results to differ materially from those expressed in these forward-looking statements. Such factors include the risk factors set forth in our Form 10-K, Form 10-Q and Form 8-K reports filed with the Securities and Exchange Commission (including all amendments to those reports) and exhibits to those reports. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement to reflect subsequent events or circumstances.